Li Mao - 18 Mar 2026 Form 3 Insider Report for Legend Biotech Corp (LEGN)

Reporting relationship: Director
Issuer ticker: LEGN
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 18:57:02 UTC
Source filing: View source filing
Reporting owner signature: /s/ James Pepin, Attorney-in-Fact

Key filing fact

Li Mao filed Form 3 for Legend Biotech Corp (LEGN) on 18 Mar 2026.

Key facts

This page summarizes Li Mao's Form 3 filing for Legend Biotech Corp (LEGN).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 18:57.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002106809 Primary reporting owner

Mao Li

Relationship: Director
Address: C/O LEGEND BIOTECH CORP, 2101 COTTONTAIL LANE, SOMERSET
Signature: /s/ James Pepin, Attorney-in-Fact
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LEGN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 44,330
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LEGN holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 30,000
Exercise price: $23.27
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

Footnote F2

Includes 25,674 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 7,136 RSUs have settled, with the remainder vesting (i) as to 2,100 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 5,888 RSUs, in 7 equal quarterly installments beginning on March 20, 2026, and (iii) as to 10,550 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Footnote F3

18,000 of the shares subject to the option are immediately exercisable and the remainder vest in 2 equal annual installments beginning on August 2, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney